SCHEMBL23748352

SCHEMBL23748352

C=CCCCNC(=O)c1[nH]ccc(=O)c1OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
TGM2 P21980 1/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24353633 0.97 POLB (0.46) POLBTGM2ALDH1A1NPC1RAB9A
SCHEMBL23748281 0.94 POLB (0.49) POLBTGM2ALDH1A1NPC1RAB9A
SCHEMBL23748321 0.87 POLB (0.51) POLBALDH1A1NPC1RAB9AKDM4E
SCHEMBL24354319 0.85 POLB (0.46) POLBALDH1A1NPC1RAB9AKDM4E
SCHEMBL21941401 0.80 POLB (0.46) POLBALDH1A1KDM4EUSP2TSHR
SCHEMBL23748282 0.79 POLB (0.53) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL10188493 0.78 POLB (0.60) POLBALDH1A1NPC1USP2TSHR
SCHEMBL24353896 0.78 POLB (0.49) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL21185114 0.78 POLB (0.46) POLBALDH1A1KDM4EUSP2TSHR
SCHEMBL10188507 0.78 POLB (0.52) POLBALDH1A1KDM4EUSP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed
CN-113195502-A Macrocyclic influenza endonuclease inhibitors 詹森生物制药有限公司 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 POLB 74/4885TGM2 3289/4885ALDH1A1 2073/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP POLB 32/4885TGM2 2920/4885ALDH1A1 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.